Merck Stock Nabs Record High After FDA Approval

Shares are today on track for their fourth-straight daily gain

Fernanda Horner

Digital Content Manager

Mar 27, 2024 at 10:19 AM

Merck & Co Inc (NYSE:MRK) was last seen up 4.4% to trade at $130.99, after the Food and Drug Administration (FDA) approved its Winrevair treatment for adults with high blood pressure due to constriction of lung arteries. The medication will be listed $14,000 per vial, with most patients expected to use one vial every three weeks.

The blue-chip stock surged to an all-time high of $133.10 right out of the gate, and is now trading well above its 20-day moving average after a brief stint below it. Shares are today on track for their fourth-straight daily gain, and added more than 26% during the past six months.

Options volume is running at eight times the intraday average so far today, with 14,00 calls and 8,918 puts across the tape so far. The most active is the May 130 call, followed by the April 130 call.

Follow @Schaeffers

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.